ClinicalTrials.gg
CompletedNCT01397825Updated Mar 27, 2018Results posted

MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine

A Phase 1/2 interventional study of Alisertib (MLN8237) and Rituximab in Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma and Mantle Cell Lymphoma, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 25 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-03-27.

Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
45
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 218 studies testing rituximab in Lymphoma, Large B-Cell, Diffuse — 20 open to participants now, 38 under way, 4 of them phase 3. Rituximab · Lymphoma, Large B-Cell, Diffuse.

Enrollment
108th of 211
45 · median 46
Started
2011
with 9 others
Phase 1/2
25 of 218
1 open now
Registered
116th of 218
by date

Among the 218 studies testing rituximab in Lymphoma, Large B-Cell, Diffuse, this one is the 108th largest by enrollment of the 211 interventional ones that give a count, is one of 10 that started in 2011, is one of 25 in phase 1/2, and was the 116th registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

20 of the 218 studies testing rituximab in Lymphoma, Large B-Cell, Diffuse are open now, in 6 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 218 studies testing rituximab in Lymphoma, Large B-Cell, Diffuse, or all of them as a file.
02

Study summary

This is a single-arm, open-label, multicenter, dose escalation, phase 1-2 study of alisertib (MLN8237) administered in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)/transformed follicular lymphoma (TFL) treated with rituximab and vincristine. The study has three parts as follows:

Phase 1, Part 1: Safety lead-in cohort to evaluate alisertib (MLN8237) and rituximab.

Phase 1, Part 2: Dose escalation cohort to evaluate alisertib (MLN8237) + Rituximab + Vincristine and determine Phase 2 dose. Patients with other types of B-cell lymphoma (including mantle cell or Burkitt's lymphoma may enroll in Parts 1 and 2.

Phase 2: Alisertib (MLN8237) + Rituximab + Vincristine in patients with relapsed or refractory DLBCL or TFL at recommended Phase 2 dose.

Note that in 2013 Sponsor decision was taken to not initiate the phase 2 portion of the trial, which would have investigated the triplet at the recommended phase 2 dose identified in part 2. This decision was based on reprioritization within the company and not on any clinical or safety outcomes observed.

Read the detailed description

The drug tested in this study was called alisertib. Alisertib was tested to treat people who have relapsed or refractory diffuse large B-cell lymphoma or other aggressive B-cell lymphomas. This study looked at safety, any anti-tumor effect, and it also determined a recommended dose of alisertib plus rituximab and alisertib plus rituximab and vincristine to take into further studies. Pharmacokinetic blood samples were studied to characterize any effects on the concentration of each of the drugs when administered together .

The study enrolled 45 patients. Participants received the following treatments:

Phase 1

  • Alisertib 50 mg + rituximab in the Safety Lead-in
  • Alisertib 30 mg + rituximab + vincristine in the Dose Escalation
  • Alisertib 40 mg + rituximab + vincristine in the Dose Escalation
  • Alisertib 50 mg + rituximab + vincristine in the Dose Escalation

All participants were asked to take one alisertib table twice a day for 7 days in each cycle for up to 8 cycles along with rituximab on Day 1 of each cycle; some patients also received vincristine on Day 1 and Day 8 of each cycle. All participants with documented disease response or stabilization could continue with alisertib single-agent therapy for an additional 2 years or more.

This multi-center trial was conducted in the USA. The overall time to participate in this study was up to 5.2 years. Participants made multiple visits to the clinic, plus a final visit 30 days after receiving their last dose of study drug for a follow-up assessment.

03

Conditions studied

  • Diffuse Large B-Cell Lymphoma
  • Transformed Follicular Lymphoma
  • Mantle Cell Lymphoma
  • Burkitt's Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed diagnosis of diffuse large B-cell lymphoma (DLBCL)/transformed follicular lymphoma (TFL). Note: Patients with Mantle Cell or Burkitt's lymphoma may be eligible for enrollment to the safety lead-in and dose escalation cohorts, parts 1 \& 2 only
  • after at least 1 prior systemic treatment for aggressive lymphoma (including anthracycline unless ). Relapse following an stem cell transplant is allowed.
  • Relapsed after autologous stem cell transplantation or not be eligible for autologous stem cell transplantation or refuse autologous stem cell transplantation. Patients enrolled to the phase 2 part must have received prior rituximab.
  • as specified in study protocol
  • (ECOG) performance status of 0 to 2
  • Female patients who are post menopausal for at least 1 year, surgically sterile, or agree to practice 2 effective methods of through 30 days after the last dose of alisertib (MLN8237) or agree to abstain from heterosexual intercourse. Patients should also use effective contraception for 12 months following the last dose of rituximab and 1 month following the last dose of alisertib (MLN8237.
  • Male patients who agree to practice effective barrier contraception through 4 months after the last dose of MLN8237 or agree to abstain from heterosexual intercourse
  • Voluntary written consent

Exclusion criteria

Exclusion Criteria

  • Received more than 4 prior systemic treatment regimens for lymphoma
  • Known (HIV) positive or acquired immunodeficiency syndrome (AIDS)-related illness; virus, or virus; known history of Charcot-Marie-Tooth disease or polio
  • stem cell transplant less than 3 months prior to enrollment
  • Patients who have undergone allogeneic stem cell or organ transplantation any time
  • Systemic antineoplastic therapy, including or treatment with an agent within 14 days preceding the first dose of study drug treatment. Steroids are permitted for administration with rituximab to prevent or treat infusion reaction
  • Treatment with nitrosoureas, mitomycin C, rituximab, alemtuzumab, or other unconjugated antibody treatment within 42 days (21 days if clear evidence of progressive disease) prior to the first day of study drug treatment
  • Treatment with radioimmunoconjugates or toxin immunoconjugates, such as ibritumomab-tiuxetan, or tositumomab, within 12 weeks prior to the first day of study drug treatment
  • Radiotherapy within 21 days prior to the first dose of study drug treatment
  • Treatment with enzyme-inducing antiepileptic drugs, such as phenytoin, carbamazepine, or phenobarbital, or with rifampin, rifabutin, rifapentine, or St. John's wort, within 14 days prior to the first dose of alisertib (MLN8237) also not permitted during study
  • Cardiac status as described in protocol
  • Major surgery, serious infection, or infection requiring systemic antibiotic therapy within 14 days prior to the first dose of study treatment
  • History of hemorrhagic or thrombotic cerebrovascular event in the past 12 months
  • Clinically uncontrolled central nervous system involvement
  • Inability to receive IV rituximab or vincristine, or to swallow tablets or inability or unwillingness to avoid taking anything by mouth except for water and prescribed medications for 2 hours before and 1 hour after each dose of alisertib (MLN8237)
  • History of uncontrolled sleep apnea syndrome and other conditions that could result in excessive daytime sleepiness
  • Female patients who are lactating or pregnant
  • Serious medical or psychiatric illness or laboratory abnormality that could, in the investigator's opinion, potentially interfere with the completion of treatment according to the protocol
  • Clinically apparent ≥ Grade 2 neuropathy due to any cause in the 3 months prior to enrollment, or history of ≥ Grade 3 neuropathy related to vincristine at any time
  • Prior treatment with Aurora A-targeted agents, including alisertib (MLN8237)
  • Patients who have received myeloid growth factors or transfusion within 14 days prior to the first dose of study treatment
  • Patients with known to rituximab, vincristine (or vinca alkaloids), or their diluents
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Safety Lead-in

    Alisertib 50 mg, enteric coated tablets (ECT), orally, twice daily (BID), on Days 1 to 7 followed by a 14-day rest period in 21-day cycles plus rituximab 375 mg/m\^2, intravenous (IV), infusion on Day 1 of each 21-day cycle for up to 8 cycles. Following 8 cycles of treatment (or early discontinuation of rituximab) all participants with documented disease response or stabilization may continue with alisertib single-agent therapy for up to 2 years.

    Drug: Alisertib (MLN8237) · Drug: Rituximab

  • Experimental
    Dose Escalation, Alisertib 30 mg

    Alisertib 30 mg, ECT, orally, BID, on Days 1 to 7 followed by a 14-day rest period plus rituximab 375 mg/m\^2, IV, infusion on Day 1, plus vincristine 1.4 mg/m\^2 (max 2 mg), IV, on Days 1 and 8 in a 21-day cycle for up to 8 cycles. Following 8 cycles of treatment (or early discontinuation of rituximab and/ or vincristine) all participants with documented disease response or stabilization may continue with alisertib single-agent therapy for up to 2 years.

    Drug: Alisertib (MLN8237) · Drug: Rituximab · Drug: Vincristine

  • Experimental
    Dose Escalation, Alisertib 40 mg

    Alisertib 40 mg, ECT, orally, BID, on Days 1 to 7 followed by a 14-day rest period plus rituximab 375 mg/m\^2, IV, infusion on Day 1 plus vincristine 1.4 mg/m\^2, IV (max 2mg), on Days 1 and 8 in a 21-day cycle for up to 8 cycles. Following 8 cycles of treatment (or early discontinuation of rituximab and/ or vincristine) all participants with documented disease response or stabilization may continue with alisertib single-agent therapy for up to 2 years.

    Drug: Alisertib (MLN8237) · Drug: Rituximab · Drug: Vincristine

  • Experimental
    Dose Escalation, Alisertib 50 mg

    Alisertib 50 mg, ECT, orally, BID, on Days 1 to 7 followed by a 14-day rest period plus rituximab 375 mg/m\^2, IV, infusion on Day 1 plus vincristine 1.4 mg/m\^2, IV (max 2mg), on Days 1 and 8 in a 21-day cycle for up to 8 cycles. Following 8 cycles of treatment (or early discontinuation of rituximab and/ or vincristine) all participants with documented disease response or stabilization may continue with alisertib single-agent therapy for up to 2 years.

    Drug: Alisertib (MLN8237) · Drug: Rituximab · Drug: Vincristine

  • Experimental
    Phase 2: Alisertib

    Phase 2: Alisertib (MLN8237) at the Recommended Phase 2 Dose, ECT orally twice/day on Days 1-7 \& rituximab as an IV infusion on Day 1 \& vincristine IV on Days 1 \& 8 in a 21 Day cycle for up to 8 cycles was planned but not conducted.

    Drug: Alisertib (MLN8237) · Drug: Rituximab · Drug: Vincristine

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Clinically Significant Vital Signs Findings (Treatment Related and Unrelated) [Phase 1]

    Vital sign parameters: blood pressure, heart rate and temperature determined by the investigator to be clinically significant were reported as adverse events.

    Time frame: First dose of alisertib through 30 days after the last dose of alisertib (Up to 5.2 Years)

  2. Number of Participants With Clinically Significant Changes in Electrocardiograms (ECGs) [Phase 1]

    Abnormal ECGs findings determined by the investigator to be clinically significant were reported as adverse events.

    Time frame: First dose of alisertib through 30 days after the last dose of alisertib (Up to 5.2 Years)

  3. Number of Participants With Clinically Significant Changes in Multigated Acquisition (MUGA)/ Echocardiogram (ECHO) [Phase 1]

    Abnormal changes in MUGA and ECHO findings determined by the investigator to be clinically significant were reported as adverse events.

    Time frame: First dose of alisertib through 30 days after the last dose of alisertib (Up to 5.2 Years)

  4. Number of Participants With Clinically Significant Changes in Physical Examination Findings [Phase 1]

    Abnormal Physical Examination findings determined by the investigator to be clinically significant were reported as Adverse Events.

    Time frame: First dose of alisertib through 30 days after the last dose of alisertib (Up to 5.2 Years)

  5. Number of Participants With Clinically Significant Laboratory Tests Reported as Adverse Events [Phase 1]

    Abnormal treatment-emergent Chemistry and Hematology Laboratory values determined by the investigator to be clinically significant were reported as adverse events.

    Time frame: First dose of alisertib through 30 days after the last dose of alisertib (Up to 5.2 Years)

  6. Number of Participants With Treatment-Emergent Adverse Events [Phase 1]

    An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.

    Time frame: First dose of alisertib through 30 days after the last dose of alisertib (Up to 5.2 Years)

  7. Overall Response Rate [Phase 2]

    Overall Response Rate was defined as the percentage of participants with Complete Response (CR) or Partial Response (PR) as assessed by the investigator using International Working Group (IWG) Criteria. CR is defined as the disappearance of all evidence of disease and PR is defined as regression of measurable disease and no new sites.

    Time frame: At the end of Cycle 2, at the end of every second treatment cycle until 6 months, then every 12 weeks thereafter, approximately 2 years

Secondary outcomes

  1. Overall Response Rate as Assessed by the Investigator [Phase 1]

    Overall Response Rate was defined as the percentage of participants with Complete Response (CR) or Partial Response (PR) as assessed by the investigator using International Working Group (IWG) Criteria. CR is defined as the disappearance of all evidence of disease and PR is defined as regression of measurable disease and no new sites.

    Time frame: First dose of alisertib through 30 days after the last dose of alisertib (Up to 5.2 Years)

  2. Complete Response Rate [Phase 2]

    Complete response rate was defined as the percentage of participants with Complete Response (CR). CR was assessed by the investigator using International Working Group (IWG) Criteria. CR is defined as the disappearance of all evidence of disease.

    Time frame: Duration of study until disease progression, approximately 2 years

  3. Duration of Response (DOR) [Phase 2]

    DOR was defined as the time from the date of first documentation of a response to the date of first documentation of Progressive Disease (PD).

    Time frame: Duration of study until disease progression, approximately 2 years

  4. Progression Free Survival (PFS) [Phase 2]

    PFS was defined as the time from the date of first study drug administration to the date of first documentation of PD or death.

    Time frame: Duration of study until disease progression, approximately 2 years

  5. Number of Participants With Treatment-Emergent Adverse Events [Phase 2]

    An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.

    Time frame: From screening period to 30 days after last dose of study drug, approximately 2 years

  6. Number of Participants With Clinically Significant Vital Signs Findings [Phase 2]

    Vital sign parameters: blood pressure, heart rate and temperature determined by the investigator to be clinically significant were reported as adverse events.

    Time frame: From screening period to 30 days after last dose of study drug, approximately 2 years

  7. Number of Participants With Clinically Significant Changes in Electrocardiograms (ECGs) [Phase 2]

    Time frame: From screening period to 30 days after last dose of study drug, approximately 2 years

  8. Number of Participants With Clinically Significant Changes in Multigated Acquisition (MUGA)/ Echocardiogram (ECHO) [Phase 2]

    Time frame: From screening period to 30 days after last dose of study drug, approximately 2 years

  9. Number of Participants With Clinically Significant Laboratory Tests Reported as Adverse Events [Phase 2]

    Time frame: From screening period to 30 days after last dose of study drug, approximately 2 years

  10. Cmax: Maximum Plasma Concentration for Alisertib

    Time frame: Cycle 1 Days 1 and 7 prior to morning alisertib dose and multiple time-points (up to 12 hours) post-dose

  11. Tmax: Time to First Occurrence of Cmax fo Alisertib

    Time frame: Cycle 1 Days 1 and 7 prior to morning alisertib dose and multiple time-points (up to 12 hours) post-dose

  12. AUCt: Area Under the Concentration Time Curve Over the Dosing Interval From Time 0 to Time t for Alisertib

    Time frame: Cycle 1 Days 1 and 7 prior to morning alisertib dose and multiple time-points (up to 12 hours) post-dose

  13. Cmax: Maximum Plasma Concentration for Vincristine

    Time frame: Cycles 1 and 2 on Day 1 prior to injection of vincristine and multiple time-points (up to 72 hours) post-dose

  14. AUCt: Area Under the Concentration-time Time Curve Over the Dosing Interval From Time 0 to Time t for Vincristine

    Time frame: Cycles 1 and 2 on Day 1 prior to injection of vincristine and multiple time-points (up to 72 hours) post-dose

  15. AUC∞: Area Under the Concentration-time Curve From Time 0 to Infinity for Vincristine

    Time frame: Cycles 1 and 2 on Day 1 prior to injection of vincristine and multiple time-points (up to 72 hours) post-dose

  16. T1/2: Terminal Disposition Phase Half-life for Vincristine

    Time frame: Cycles 1 and 2 on Day prior to injection of vincristine and multiple time-points (up to 72 hours) post-dose

07

Results

Posted Mar 27, 2018
Limitations and caveats
The Phase 2 portion of the study was cancelled by the sponsor; this was an administrative decision not based on any clinical or safety outcomes.

Participant flow

Participants took part in the Phase 1 portion of the study at 10 investigative sites in the United States from 09 August 2011 to 05 October 2016. The Phase 2 portion of the study was cancelled by the sponsor.

Participant flow — Overall Study
MilestoneSafety Lead-inDose Escalation, Alisertib 30 mgDose Escalation, Alisertib 40 mgDose Escalation, Alisertib 50 mgPhase 2: Alisertib
Started1342530
Completed00000
Not completed1342530
Withdrew: Progressive disease1031110
Withdrew: Symptomatic deterioration20400
Withdrew: Adverse event01510
Withdrew: Withdrawal by subject10510

Outcome measures

PrimaryNumber of Participants With Clinically Significant Vital Signs Findings (Treatment Related and Unrelated) [Phase 1]

Vital sign parameters: blood pressure, heart rate and temperature determined by the investigator to be clinically significant were reported as adverse events.

Time frame:
First dose of alisertib through 30 days after the last dose of alisertib (Up to 5.2 Years)
Reported as:
Number · participants
Number of Participants With Clinically Significant Vital Signs Findings (Treatment Related and Unrelated) [Phase 1]
participantsSafety Lead-inDose Escalation, Alisertib 30 mgDose Escalation, Alisertib 40 mgDose Escalation, Alisertib 50 mg
Hypotension0031
Orthostatic hypotension2200
Hypertension1000
Pyrexia3021
PrimaryNumber of Participants With Clinically Significant Changes in Electrocardiograms (ECGs) [Phase 1]

Abnormal ECGs findings determined by the investigator to be clinically significant were reported as adverse events.

Time frame:
First dose of alisertib through 30 days after the last dose of alisertib (Up to 5.2 Years)
Reported as:
Number · participants
Number of Participants With Clinically Significant Changes in Electrocardiograms (ECGs) [Phase 1]
participantsSafety Lead-inDose Escalation, Alisertib 30 mgDose Escalation, Alisertib 40 mgDose Escalation, Alisertib 50 mg
Number of Participants With Clinically Significant Changes in Electrocardiograms (ECGs) [Phase 1]0000
PrimaryNumber of Participants With Clinically Significant Changes in Multigated Acquisition (MUGA)/ Echocardiogram (ECHO) [Phase 1]

Abnormal changes in MUGA and ECHO findings determined by the investigator to be clinically significant were reported as adverse events.

Time frame:
First dose of alisertib through 30 days after the last dose of alisertib (Up to 5.2 Years)
Reported as:
Number · participants
Number of Participants With Clinically Significant Changes in Multigated Acquisition (MUGA)/ Echocardiogram (ECHO) [Phase 1]
participantsSafety Lead-inDose Escalation, Alisertib 30 mgDose Escalation, Alisertib 40 mgDose Escalation, Alisertib 50 mg
Number of Participants With Clinically Significant Changes in Multigated Acquisition (MUGA)/ Echocardiogram (ECHO) [Phase 1]0000
PrimaryNumber of Participants With Clinically Significant Changes in Physical Examination Findings [Phase 1]

Abnormal Physical Examination findings determined by the investigator to be clinically significant were reported as Adverse Events.

Time frame:
First dose of alisertib through 30 days after the last dose of alisertib (Up to 5.2 Years)
Reported as:
Number · participants
Number of Participants With Clinically Significant Changes in Physical Examination Findings [Phase 1]
participantsSafety Lead-inDose Escalation, Alisertib 30 mgDose Escalation, Alisertib 40 mgDose Escalation, Alisertib 50 mg
Number of Participants With Clinically Significant Changes in Physical Examination Findings [Phase 1]0022
PrimaryNumber of Participants With Clinically Significant Laboratory Tests Reported as Adverse Events [Phase 1]

Abnormal treatment-emergent Chemistry and Hematology Laboratory values determined by the investigator to be clinically significant were reported as adverse events.

Time frame:
First dose of alisertib through 30 days after the last dose of alisertib (Up to 5.2 Years)
Reported as:
Number · participants
Number of Participants With Clinically Significant Laboratory Tests Reported as Adverse Events [Phase 1]
participantsSafety Lead-inDose Escalation, Alisertib 30 mgDose Escalation, Alisertib 40 mgDose Escalation, Alisertib 50 mg
Anaemia63142
Neutropenia72112
Febrile neutropenia0043
Leukopenia8293
Lymphopenia2211
Thrombocytopenia7173
Hypokalaemia5062
Hyperkalaemia0010
Hypomagnesaemia2051
Hypermagnesaemia0001
Hypocalcaemia2011
Hypercalcaemia1020
Hyperglycaemia1121
Hypoalbuminaemia3002
Hyponatraemia2001
Hypernatraemia0010
Hypophosphataemia1011
Neutrophil count decreased1031
Lymphocyte count decreased1000
White blood cell count decreased0001
Aspartate aminotransferase increased0012
Alanine aminotransferase increased0002
Blood bilirubin increased1000
Platelet count decreased1011
PrimaryNumber of Participants With Treatment-Emergent Adverse Events [Phase 1]

An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.

Time frame:
First dose of alisertib through 30 days after the last dose of alisertib (Up to 5.2 Years)
Reported as:
Number · participants
Number of Participants With Treatment-Emergent Adverse Events [Phase 1]
participantsSafety Lead-inDose Escalation, Alisertib 30 mgDose Escalation, Alisertib 40 mgDose Escalation, Alisertib 50 mg
Number of Participants With Treatment-Emergent Adverse Events [Phase 1]134253
PrimaryOverall Response Rate [Phase 2]

Overall Response Rate was defined as the percentage of participants with Complete Response (CR) or Partial Response (PR) as assessed by the investigator using International Working Group (IWG) Criteria. CR is defined as the disappearance of all evidence of disease and PR is defined as regression of measurable disease and no new sites.

Time frame:
At the end of Cycle 2, at the end of every second treatment cycle until 6 months, then every 12 weeks thereafter, approximately 2 years

No measurements were reported for this outcome.

SecondaryOverall Response Rate as Assessed by the Investigator [Phase 1]

Overall Response Rate was defined as the percentage of participants with Complete Response (CR) or Partial Response (PR) as assessed by the investigator using International Working Group (IWG) Criteria. CR is defined as the disappearance of all evidence of disease and PR is defined as regression of measurable disease and no new sites.

Time frame:
First dose of alisertib through 30 days after the last dose of alisertib (Up to 5.2 Years)
Reported as:
Number · percentage of participants
Overall Response Rate as Assessed by the Investigator [Phase 1]
percentage of participantsSafety Lead-inDose Escalation, Alisertib 30 mgDose Escalation, Alisertib 40 mgDose Escalation, Alisertib 50 mg
Overall Response Rate as Assessed by the Investigator [Phase 1]25 (5 to 57)33 (0.84 to 91)45 (23 to 68)50 (1 to 99)
SecondaryComplete Response Rate [Phase 2]

Complete response rate was defined as the percentage of participants with Complete Response (CR). CR was assessed by the investigator using International Working Group (IWG) Criteria. CR is defined as the disappearance of all evidence of disease.

Time frame:
Duration of study until disease progression, approximately 2 years

No measurements were reported for this outcome.

SecondaryDuration of Response (DOR) [Phase 2]

DOR was defined as the time from the date of first documentation of a response to the date of first documentation of Progressive Disease (PD).

Time frame:
Duration of study until disease progression, approximately 2 years

No measurements were reported for this outcome.

SecondaryProgression Free Survival (PFS) [Phase 2]

PFS was defined as the time from the date of first study drug administration to the date of first documentation of PD or death.

Time frame:
Duration of study until disease progression, approximately 2 years

No measurements were reported for this outcome.

SecondaryNumber of Participants With Treatment-Emergent Adverse Events [Phase 2]

An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.

Time frame:
From screening period to 30 days after last dose of study drug, approximately 2 years

No measurements were reported for this outcome.

SecondaryNumber of Participants With Clinically Significant Vital Signs Findings [Phase 2]

Vital sign parameters: blood pressure, heart rate and temperature determined by the investigator to be clinically significant were reported as adverse events.

Time frame:
From screening period to 30 days after last dose of study drug, approximately 2 years

No measurements were reported for this outcome.

SecondaryNumber of Participants With Clinically Significant Changes in Electrocardiograms (ECGs) [Phase 2]
Time frame:
From screening period to 30 days after last dose of study drug, approximately 2 years

No measurements were reported for this outcome.

SecondaryNumber of Participants With Clinically Significant Changes in Multigated Acquisition (MUGA)/ Echocardiogram (ECHO) [Phase 2]
Time frame:
From screening period to 30 days after last dose of study drug, approximately 2 years

No measurements were reported for this outcome.

SecondaryNumber of Participants With Clinically Significant Laboratory Tests Reported as Adverse Events [Phase 2]
Time frame:
From screening period to 30 days after last dose of study drug, approximately 2 years

No measurements were reported for this outcome.

SecondaryCmax: Maximum Plasma Concentration for Alisertib
Time frame:
Cycle 1 Days 1 and 7 prior to morning alisertib dose and multiple time-points (up to 12 hours) post-dose
Reported as:
Mean · nanoMolar (nM)
Cmax: Maximum Plasma Concentration for Alisertib
nanoMolar (nM)Safety Lead-inDose Escalation, Alisertib 30 mgDose Escalation, Alisertib 40 mgDose Escalation, Alisertib 50 mg
Day 11624.1 ± 929.68893.3 ± 350.031159.7 ± 391.781746.7 ± 594.75
Day 72915.8 ± 1537.031672.5 ± 183.922223.3 ± 1217.223670.0 ± 1541.49
SecondaryTmax: Time to First Occurrence of Cmax fo Alisertib
Time frame:
Cycle 1 Days 1 and 7 prior to morning alisertib dose and multiple time-points (up to 12 hours) post-dose
Reported as:
Median · hours (hr)
Tmax: Time to First Occurrence of Cmax fo Alisertib
hours (hr)Safety Lead-inDose Escalation, Alisertib 30 mgDose Escalation, Alisertib 40 mgDose Escalation, Alisertib 50 mg
Day 13.0 (2 to 8)3.5 (3 to 6)3.0 (1 to 12)6.1 (3 to 12)
Day 72.0 (0 to 8)3.1 (2 to 6)3.1 (2 to 8)2.5 (2 to 3)
SecondaryAUCt: Area Under the Concentration Time Curve Over the Dosing Interval From Time 0 to Time t for Alisertib
Time frame:
Cycle 1 Days 1 and 7 prior to morning alisertib dose and multiple time-points (up to 12 hours) post-dose
Reported as:
Mean · nanomoles/liter*hour (nmol/L*hr)
AUCt: Area Under the Concentration Time Curve Over the Dosing Interval From Time 0 to Time t for Alisertib
nanomoles/liter*hour (nmol/L*hr)Safety Lead-inDose Escalation, Alisertib 30 mgDose Escalation, Alisertib 40 mgDose Escalation, Alisertib 50 mg
Day 110116.7 ± 6683.975817.5 ± 2966.268005.9 ± 3251.3213096.7 ± 7453.39
Day 721812.5 ± 13090.2112227.5 ± 3480.0917996.0 ± 11555.1533800.0 ± 16263.46
SecondaryCmax: Maximum Plasma Concentration for Vincristine
Time frame:
Cycles 1 and 2 on Day 1 prior to injection of vincristine and multiple time-points (up to 72 hours) post-dose
Reported as:
Mean · ng/mL
Cmax: Maximum Plasma Concentration for Vincristine
ng/mLDose Escalation, Alisertib 30 mgDose Escalation, Alisertib 40 mgDose Escalation, Alisertib 50 mg
Cycle 1, Day 1132.2 ± 54.57105.4 ± 78.93158.4 ± 67.94
Cycle 2, Day 1113.9 ± 53.86124.4 ± 157.70122.3 ± 36.42
SecondaryAUCt: Area Under the Concentration-time Time Curve Over the Dosing Interval From Time 0 to Time t for Vincristine
Time frame:
Cycles 1 and 2 on Day 1 prior to injection of vincristine and multiple time-points (up to 72 hours) post-dose
Reported as:
Mean · ng/mL*hr
AUCt: Area Under the Concentration-time Time Curve Over the Dosing Interval From Time 0 to Time t for Vincristine
ng/mL*hrDose Escalation, Alisertib 30 mgDose Escalation, Alisertib 40 mgDose Escalation, Alisertib 50 mg
Cycle 1, Day 169.8 ± 9.9269.1 ± 33.24104.1 ± 43.34
Cycle 2, Day 160.8 ± 2.2672.8 ± 30.4072.2 ± 32.60
SecondaryAUC∞: Area Under the Concentration-time Curve From Time 0 to Infinity for Vincristine
Time frame:
Cycles 1 and 2 on Day 1 prior to injection of vincristine and multiple time-points (up to 72 hours) post-dose
Reported as:
Mean · ng/mL*hr
AUC∞: Area Under the Concentration-time Curve From Time 0 to Infinity for Vincristine
ng/mL*hrDose Escalation, Alisertib 30 mgDose Escalation, Alisertib 40 mgDose Escalation, Alisertib 50 mg
Cycle 1, Day 177.9 ± 11.2584.8 ± 36.21116.8 ± 44.95
Cycle 2, Day 169.0 ± 4.4582.7 ± 35.39—
SecondaryT1/2: Terminal Disposition Phase Half-life for Vincristine
Time frame:
Cycles 1 and 2 on Day prior to injection of vincristine and multiple time-points (up to 72 hours) post-dose
Reported as:
Mean · nanogram/milliliter (ng/mL)
T1/2: Terminal Disposition Phase Half-life for Vincristine
nanogram/milliliter (ng/mL)Dose Escalation, Alisertib 30 mgDose Escalation, Alisertib 40 mgDose Escalation, Alisertib 50 mg
Cycle 1, Day 120.2 ± 5.0420.0 ± 5.8925.6 ± 4.55
Cycle 2, Day 119.9 ± 0.9220.2 ± 4.66—

Adverse events

Collected over First dose of alisertib through 30 days after the last dose of alisertib (Up to 5.2 Years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Safety Lead-in—6/13 (46.2%)13/13 (100%)
Dose Escalation, Alisertib 30 mg—1/4 (25%)4/4 (100%)
Dose Escalation, Alisertib 40 mg—12/25 (48%)25/25 (100%)
Dose Escalation, Alisertib 50 mg—3/3 (100%)3/3 (100%)
Most frequent serious events
Showing 10 of 35
Most frequent serious events
EventSafety Lead-inDose Escalation, Alisertib 30 mgDose Escalation, Alisertib 40 mgDose Escalation, Alisertib 50 mg
Febrile neutropeniaBlood and lymphatic system disorders0/130/43/253/3
StomatitisGastrointestinal disorders0/130/40/252/3
ThrombocytopeniaBlood and lymphatic system disorders0/130/40/251/3
FatigueGeneral disorders0/130/40/251/3
Clostridium difficile colitisInfections and infestations0/130/40/251/3
Enterobacter bacteraemiaInfections and infestations0/130/40/251/3
Spinal cord neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/131/40/250/3
Spinal cord compressionNervous system disorders0/131/40/250/3
AnaemiaBlood and lymphatic system disorders2/130/41/250/3
PyrexiaGeneral disorders2/130/42/250/3
Most frequent other events
Showing 10 of 130
Most frequent other events
EventSafety Lead-inDose Escalation, Alisertib 30 mgDose Escalation, Alisertib 40 mgDose Escalation, Alisertib 50 mg
LeukopeniaBlood and lymphatic system disorders8/132/49/253/3
ThrombocytopeniaBlood and lymphatic system disorders7/131/48/253/3
AnaemiaBlood and lymphatic system disorders6/133/415/252/3
NeutropeniaBlood and lymphatic system disorders7/132/411/252/3
FatigueGeneral disorders4/132/411/252/3
HypokalaemiaMetabolism and nutrition disorders4/130/46/252/3
HypoalbuminaemiaMetabolism and nutrition disorders3/130/40/252/3
Urinary tract infectionInfections and infestations1/130/46/252/3
Aspartate aminotransferase increasedInvestigations0/130/41/252/3
Alanine aminotransferase increasedInvestigations0/130/40/252/3

Baseline characteristics

Safety Population was defined as all participants who receive any amount of alisertib.

Age, Continuous
Age, Continuous(years)Safety Lead-inDose Escalation, Alisertib 30 mgDose Escalation, Alisertib 40 mgDose Escalation, Alisertib 50 mgTotal
Mean60.3 ± 14.0651.3 ± 21.6562.8 ± 10.5166.7 ± 12.8661.3 ± 12.89
Sex: Female, Male
Sex: Female, Male(Participants)Safety Lead-inDose Escalation, Alisertib 30 mgDose Escalation, Alisertib 40 mgDose Escalation, Alisertib 50 mgTotal
Female3110216
Male10315129
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Safety Lead-inDose Escalation, Alisertib 30 mgDose Escalation, Alisertib 40 mgDose Escalation, Alisertib 50 mgTotal
Hispanic or Latino716115
Not Hispanic or Latino6319230
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Safety Lead-inDose Escalation, Alisertib 30 mgDose Escalation, Alisertib 40 mgDose Escalation, Alisertib 50 mgTotal
White12421340
Black or African American00202
Asian10001
Other00101
Not Reported00101
Region of Enrollment
Region of Enrollment(participants)Safety Lead-inDose Escalation, Alisertib 30 mgDose Escalation, Alisertib 40 mgDose Escalation, Alisertib 50 mgTotal
United States13425345
Height
Height(cm)Safety Lead-inDose Escalation, Alisertib 30 mgDose Escalation, Alisertib 40 mgDose Escalation, Alisertib 50 mgTotal
Mean167.9 ± 10.90178.2 ± 7.15168.4 ± 10.76166.5 ± 5.32169.0 ± 10.44
Weight
Weight(kg)Safety Lead-inDose Escalation, Alisertib 30 mgDose Escalation, Alisertib 40 mgDose Escalation, Alisertib 50 mgTotal
Mean70.98 ± 16.1889.51 ± 23.8982.21 ± 16.471.94 ± 14.5578.93 ± 17.46
Body Surface Area
Body Surface Area(m^2)Safety Lead-inDose Escalation, Alisertib 30 mgDose Escalation, Alisertib 40 mgDose Escalation, Alisertib 50 mgTotal
Mean1.815 ± 0.252.093 ± 0.311.940 ± 0.231.823 ± 0.211.910 ± 0.25
08

Study locations

25 sites
  • Tucson, Arizona, United States
  • Beverly Hills, California, United States
  • Burbank, California, United States
  • Miami, Florida, United States
  • Lexington, Kentucky, United States
  • Worcester, Massachusetts, United States
  • New York, New York, United States
  • Rochester, New York, United States
  • Chapel Hill, North Carolina, United States
  • Philadelphia, Pennsylvania, United States
  • Germantown, Tennessee, United States
  • Memphis, Tennessee, United States
  • Houston, Texas, United States
  • San Antonio, Texas, United States
  • Burlington, Vermont, United States
  • Orbassano, Torino, Italy
  • Genova, Italy
  • Palermo, Italy
  • Roma, Italy
  • Madrid, Spain
  • Sevilla, Spain
  • Aberdeen, Grampian Region, United Kingdom
  • London, Greater London, United Kingdom
  • Southampton, Hampshire, United Kingdom
  • Birmingham, West Midlands, United Kingdom
09

References and documents

Publications

  • Kelly KR, Friedberg JW, Park SI, McDonagh K, Hayslip J, Persky D, Ruan J, Puvvada S, Rosen P, Iyer SP, Stefanovic A, Bernstein SH, Weitman S, Karnad A, Monohan G, VanderWalde A, Mena R, Schmelz M, Spier C, Groshen S, Venkatakrishnan K, Zhou X, Sheldon-Waniga E, Leonard EJ, Mahadevan D. Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma. Clin Cancer Res. 2018 Dec 15;24(24):6150-6159. doi: 10.1158/1078-0432.CCR-18-0286. Epub 2018 Aug 6. PubMed 30082475 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2011 to primary completion in Feb 2015, 41 months.

Results were first posted in Mar 2018, 3 years 1 month after primary completion. A results delay was requested in Nov 2016.

Of 51 industry-sponsored phase 1/2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 54 and three quarters within 99. This study's 41 months is below that.

Counting every sponsor, half of 108 studies reached it within 70 months; a quarter within 50 and three quarters within 98.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2011
First posted
Jul 20, 2011
StartActual
Aug 9, 2011
Primary completionActual
Feb 5, 2015
CompletionActual
Oct 5, 2016
Results delay requested
Nov 17, 2016
Results first posted
Mar 27, 2018
Last update
Mar 27, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01397825
Responsible party
Sponsor
First posted
Jul 20, 2011
Start date
Aug 9, 2011
Primary completion
Feb 5, 2015
Completion
Oct 5, 2016
Results posted
Mar 27, 2018
Last update
Mar 27, 2018

Study contacts

Medical Monitor
study director · Millennium Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: MLN 8237 · Rituximab

Start the discussion